Maintenance Strategies for Myeloma Is Bigger Always Better?

Over the last decade, several very important prospective randomized controlled trials have confirmed the significant survival benefit conferred by maintenance therapies. Owing to these developments, the role of continued maintenance in the optimal management strategies of newly diagnosed myeloma patients (both transplant-eligible and transplant-ineligible) has been strongly cemented. In dealing with an incurable disease such as myeloma, whether to offer maintenance is no longer as relevant a question as it was before, but which antimyeloma agent or agents to use, as maintenance remains more pertinent today. More importantly, a personalized risk-stratified maintenance approach for an individual patient to yield the best benefit for that specific patient is yet to be uniformly adapted. In this article, we review the available and evolving clinical data leading to our current-day practices, and we make an effort to describe what lies ahead.

Automated summary

In the past decade, research on maintenance therapy has confirmed its significant survival benefits, making it an important component of treatment for newly diagnosed myeloma patients. However, the challenge lies in selecting the most appropriate antimyeloma agents for maintenance therapy for each patient.